298 In the index

GSK-2881078 GSK

An experimental muscle-building compound from a major drug company, tested in a small human trial for muscle wasting caused by lung disease and cancer. That early trial showed real muscle gains with tolerable short-term side effects, but the drug was never advanced to larger trials or approved.

Also known as GSK2881078, 47M5ZXU844, RefChem:144556, 855-390-2, GSK 2881078, orb1303992, GSK'078, EX-A2336, S0276

Effects Build muscle

Routes Oral

Legal status Research chemical

WADA Banned at all times

3D Molecular Structure of C₁₄H₁₃F₃N₂O₂S

Drag to rotate · scroll to zoom

Chemistry

Formula: C14H13F3N2O2S
Molar mass: 330.33
CAS: 1539314-06-1
PubChem CID: 86709174
IUPAC name: 1-[(2R)-1-methylsulfonylpropan-2-yl]-4-(trifluoromethyl)indole-5-carbonitrile
InChIKey: SKDVMPZQJMZEAC-SECBINFHSA-N

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established (development discontinued)

Reported range Phase I/II trial doses: 0.5-2.5 mg/day (studied in COPD/muscle-wasting patients)

Route Oral

Frequency Once daily (trial protocol)

Duration Trial durations of a few weeks to months

A SARM candidate that completed some Phase II work in muscle wasting before development stalled; not an approved product.

Where this comes from Published Phase I/II clinical trial data (GlaxoSmithKline)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.